Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;11(8):847-855.
doi: 10.4155/fmc-2018-0313. Epub 2019 Apr 17.

Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders

Maria J Barahona  1 , Vanessa Baratta  1 , Jenna Ollodart  1 , David Mulligan  1 , John P Geibel  1   2
Affiliations
Review

Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders

Maria J Barahona et al. Future Med Chem. 2019 Apr.

Abstract

Gastrointestinal illnesses pose a significant worldwide disease burden and are associated with an array of medicinal and surgical therapies. Standard pharmaceutical options have adverse effects, prompting the rise of nutraceutical or food-derivative therapies. Here, we present an overview of the current nutraceutical therapies in gastrointestinal disease. We then introduce the calcium-sensing receptor (CaSR) as a novel therapeutic target. A G-protein-coupled receptor found in apical and basal intestinal cells, the CaSR modulates intestinal fluid secretion and mucosal integrity. Applying nutraceuticals that upregulate the CaSR may alleviate symptoms seen across a spectrum of illnesses. At last, we discuss how nanoparticle technology can be implemented to effectively deliver nutraceuticals to diseased regions of the intestine, thereby minimizing systemic side effects.

Keywords: calcium-sensing receptor; gastrointestinal disorders; inflammation; nanoparticles; nutraceutical; pharmaceutical.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported by the Charles Ohse Grant of the Department of Surgery, Yale University School of Medicine. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Model showing CaSR-mediated downregulation of cAMP/cGMP secretagogue effects on fluid transport in colonocytes.
CaSR: Calcium-sensing receptor. Reproduced with permission from [48] © National Academy of Sciences, USA (2006).
<b>Figure 2.</b>
Figure 2.. Schematic model showing CaSR with three proposed Ca2+-binding sites.
CaSR: Calcium-sensing receptor. Reproduced with permission from [53].
See this image and copyright information in PMC

References

    1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511. - PubMed
    1. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126(6):1518–1532. - PubMed
    1. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407. - PubMed
    1. Gul K, Singh AK, Jabeen R. Nutraceuticals and functional foods: the foods for the future world. Crit. Rev. Food Sci. Nutr. 2016;56(16):2617–2627. - PubMed
    1. Yang N, Sampathkumar K, Loo SCJ. Recent advances in complementary and replacement therapy with nutraceuticals in combating gastrointestinal illnesses. Clin. Nutr. 2017;36(4):968–979. - PubMed

Publication types

MeSH terms

Substances